Latest news and press releases about BeyondSpring Inc. (BYSI): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer.
Price
| Price | $0.71 |
| Market Cap | $29M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -0.82 |
| EV / EBITDA | -2.91 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 19.96% |
| Return on Invested Capital | -1429.62% |
| Return on Assets | -45.77% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALXO · ATYR · BMEA · CAMP · DTIL · GUTS · HYFT
Explore sector: Healthcare · Biotechnology
More sections of BYSI: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks